trial
as of 2026-07-01"Extended" (Alternate Day) Antipsychotic Dosing
NCTId NCT04478838
at a glance
Phase 4 · Recruiting
Enrollment 120 (estimated)
Sponsored by Centre for Addiction and Mental Health
Primary completion 2027-09-30
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Recruiting
Enrollment
120 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2022-06-06
Primary completion
2027-09-30
Eligibility
ALL · 18 Years
Interventions & indications
Sponsors
Centre for Addiction and Mental HealthLead Sponsor
Investigators
1
Gary Remington, MD PhD FRCPCPrincipal Investigator
Sites
1 total
Toronto, Canada
Facts & assertions
4 sourced
Enrollment
120
Phase
PHASE4
Primary Completion Date
2027-09-30
Status
RECRUITING
relationships
The graph out of here
drug
lead_sponsor
indication
investigator